A diagnosis of type 1 diabetes (T1D) is missed less frequently when patients present during childhood or adolescence, but unlike in adults, misdiagnosis in childhood is associated with an increased likelihood of diabetic ketoacidosis.
A section on the use of technology in the management of diabetes has been added to the American Diabetes Association Standards of Medical Care in Diabetes.
The FDA has granted Breakthrough Therapy designation to teplizumab (PRV-031; Provention Bio), for the prevention or delay of clinical T1D in those at risk of developing the disease.
The FDA has approved Myxredlin (Baxter), the first ready-to-use insulin for intravenous (IV) infusion for use in acute care settings under medical supervision.
Dapagliflozin was recently approved for T1D in Europe and Japan.
Researchers conducted a retrospective chart review on patients from an endocrinology clinic who initiated a GLP-1 agonist and/or SGLT-2 inhibitor after receiving U-500 insulin for at least 3 months.
Abbott has launched the Afinion HbA1c Dx assay, a point of care (POC) glycated hemoglobin (HbA1c) test that provides results in 3 minutes.
The prevalence of diagnosed diabetes has plateaued during the last eight years, while the incidence has declined.
Years before the first closed-loop insulin delivery system was approved, patients with diabetes had already been implementing the technology into their own care.
